Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,133 matching trials from the live ClinicalTrials.gov search.
Filters: "HER2-positive" Condition: Breast Cancer Clear all
Completed Phase 2 Interventional Results available

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

NCT02073487
View directory record Official record
Conditions
Breast Cancer
Interventions
T-DM1, Trastuzumab, Lapatinib, Abraxane, Paclitaxel, Pertuzumab
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 17, 2026, 10:21 PM EDT
Recruiting Phase 3 Interventional

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

NCT06058377
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Interventions
Biospecimen Collection, Cyclophosphamide, Doxorubicin, Durvalumab, Genetic Testing, Mammography, Paclitaxel, Quality-of-Life Assessment
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3,680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
558
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 429 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 10:21 PM EDT
Completed Phase 2 Interventional

Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

NCT00136539
View directory record Official record
Conditions
Breast Cancer
Interventions
Herceptin, Taxol, Adriamycin, Cytoxan
Drug
Lead sponsor
Harold J. Burstein, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2013 · Synced Oct 17, 2026, 10:21 PM EDT
Completed Phase 2 Interventional Results available

Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification

NCT02177175
View directory record Official record
Conditions
Breast Cancer
Interventions
Carvedilol, placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 17, 2026, 10:21 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer

NCT02658084
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
Vinorelbine, Trastuzumab Emtansine
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 17, 2026, 10:21 PM EDT
Recruiting Not applicable Interventional

A Study of the TheraBionic P1 Device in Breast Cancer

NCT07218432
View directory record Official record
Conditions
Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage IIIA, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer
Interventions
TheraBionic P1 Device
Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
22 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Clarkston, Michigan • Detroit, Michigan • Farmington Hills, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 17, 2026, 10:21 PM EDT
Completed Phase 1 Interventional Results available

A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer

NCT03916744
View directory record Official record
Conditions
Breast Cancer
Interventions
Giredestrant, Surgery
Drug · Procedure
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 17, 2026, 10:21 PM EDT
Recruiting Phase 2 Interventional

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

NCT05325632
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
HER-2 pulsed DC1, Trastuzumab, Pertuzumab, Paclitaxel, Resection surgery
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 17, 2026, 10:21 PM EDT
Recruiting Not applicable Interventional

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA

NCT03769415
View directory record Official record
Conditions
Breast Cancer
Interventions
Intrinsic Subtyping of Primary Breast Cancer
Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 17, 2026, 10:21 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management

NCT07242118
View directory record Official record
Conditions
Breast Cancer Female
Interventions
SABR
Radiation
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 17, 2026, 10:21 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

NCT06726148
View directory record Official record
Conditions
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Interventions
ECI830, ribociclib, fulvestrant
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Los Angeles, California • Fort Myers, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 17, 2026, 10:21 PM EDT
Completed No phase listed Observational

Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts

NCT02752893
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 17, 2026, 10:21 PM EDT
Completed Phase 1 Interventional

A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

NCT01983501
View directory record Official record
Conditions
HER2 Positive Breast Cancers
Interventions
Tucatinib (ONT-380), T-DM1
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Aurora, Colorado • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 17, 2026, 10:21 PM EDT
Withdrawn Phase 4 Interventional

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

NCT03988114
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
70
States / cities
Daphne, Alabama • Tempe, Arizona • Fountain Valley, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 17, 2026, 10:21 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

NCT01610284
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, BKM120, BKM120 matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
61
States / cities
Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 17, 2026, 10:21 PM EDT
Recruiting Phase 1 Interventional

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

NCT05504707
View directory record Official record
Conditions
Triple Negative Breast Cancer, HER2-negative Breast Cancer
Interventions
HER2 - primed Dendritic cells, HER3 - primed Dendritic cells
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 17, 2026, 10:21 PM EDT
Completed Phase 1Phase 2 Interventional

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

NCT03377387
View directory record Official record
Conditions
Breast Cancer
Interventions
Capecitabine, Neratinib, EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30
Drug · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
10
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 10:21 PM EDT
Active, not recruiting Phase 2 Interventional Results available

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

NCT03414658
View directory record Official record
Conditions
Breast Cancer
Interventions
Vinorelbine, Trastuzumab, Avelumab, Utomilumab
Drug
Lead sponsor
Adrienne G. Waks
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 17, 2026, 10:21 PM EDT
Recruiting No phase listed Observational

HER2-positive Breast Cancer Registry

NCT06603597
View directory record Official record
Conditions
HER2 + Breast Cancer
Interventions
Not listed
Lead sponsor
Priyanka Sharma
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2044
U.S. locations
6
States / cities
Overland Park, Kansas • Westwood, Kansas • Lee's Summit, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 17, 2026, 10:21 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

NCT00266110
View directory record Official record
Conditions
Breast Cancer
Interventions
sargramostim, therapeutic autologous dendritic cells, trastuzumab, vinorelbine ditartrate
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 17, 2026, 10:21 PM EDT
Recruiting Phase 2 Interventional

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

NCT05020860
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm, Breast Cancer Female, Breast Cancer Invasive, Breast Cancer Stage II, Breast Cancer Stage III, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Neoplasms, Estrogen Receptor-positive Breast Cancer
Interventions
Paclitaxel, Carboplatin, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Pembrolizumab, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 17, 2026, 10:21 PM EDT
Completed No phase listed Observational

Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal

NCT07223476
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
1,926 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 17, 2026, 10:21 PM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

NCT01355393
View directory record Official record
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
HER-2/neu peptide vaccine, sargramostim, rintatolimod
Biological · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 17, 2026, 10:21 PM EDT
Completed Phase 1 Interventional

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

NCT02338349
View directory record Official record
Conditions
Advanced ER+, HER2-Negative Breast Cancer
Interventions
Elacestrant
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 17, 2026, 10:21 PM EDT